TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03623685

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: measurement of uterocervical angle
Description: We will measure between internal cervikal os and external cervical os. After we will draw a line between anterior uterine wall and internal cervical os. Then we will measure angle between two lines
Study: NCT02974088

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neem-based lotion plus louse comb
Description: Neem-based conditioning lotion was applied to washed and towel dried hair followed by systematic combing using a head louse detection and removal comb

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neem-based lotion plus grooming comb
Description: Neem-based conditioning lotion was applied to washed and towel dried hair followed by combing through using a regular grooming comb
Study: NCT02886767

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skin to skin contact
Description: The researchers facilitated initial SSC between intervention-group participants and their infants within 24 hours of birthing under conditions that did not adversely affect spontaneous mother-infant SSC nor interfere with the early initiation of breastfeeding. Because it is standard practice to discharge vaginal-birth mothers on the third postpartum day, this study implemented the intervention during the first three postpartum days for both vaginal and cesarean birth cases.
Study: NCT02039791

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: 200mg/w,weekly, 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 6, d1，1 cycle/21d, 2 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m2, d1~1 cycle/21d, 2 cycles.
Study: NCT03423823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziv-Aflibercept 25 MG/ML [Zaltrap]
Description: Anti-VEGF injection

Intervention type: DRUG
Group type: OTHER
Intervention: Ranibizumab
Description: Anti-VEGF standard of care injection
Study: NCT02853721

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iPTH
Description: iPTH assay six hours after surgery

Intervention type: OTHER
Group type: OTHER
Intervention: no dosage of iPTH
Description: Ca and P on postoperative day 1 and 2
Study: NCT04773613

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental SLP
Description: SLP was given to the infant during bottle-feeding.

Intervention type: OTHER
Group type: OTHER
Intervention: Experimental SEP
Description: SEP was given to the infant during bottle-feeding.
Study: NCT00550368

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological intervention: Enteropathogenic E. coli
Description: 5x10\^8 or 1x10\^9 organisms of EPEC were administered to all participants.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological intervention: Enteropathogenic E. coli
Description: 5x10\^8 or 1x10\^9 organisms of EPEC were administered to all participants.
Study: NCT04193267

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MagStim Rapid2 Transcranial Magnetic Simulation
Description: A non-invasive method of brain stimulation
Study: NCT03462472

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lower leg heating
Description: Immersion of lower legs in a circulating water bath at a temperature of 42 degrees Celsius

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lower leg heating
Description: Immersion of lower legs in a circulating water bath at a temperature of 42 degrees Celsius

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lower leg transcutaneous electrical nerve stimulation (TENS)
Description: Bilateral lower leg transcutaneous electrical nerve stimulation (TENS) using burst mode at a 3Hz burst rate, 100Hz frequency, and 250 µs pulse duration, sufficient to evoke skeletal muscle contraction

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lower leg transcutaneous electrical nerve stimulation (TENS)
Description: Bilateral lower leg transcutaneous electrical nerve stimulation (TENS) using burst mode at a 3Hz burst rate, 100Hz frequency, and 250 µs pulse duration, sufficient to evoke skeletal muscle contraction
Study: NCT02465463

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplant (FMT)
Description: 250 mL of donor stool will be infused into the colon by flexible sigmoidoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: flexible sigmoidoscopy
Study: NCT02716467

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intercessory prayer
Description: Intercessory prayer will be offered by a group of six Christian people.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: All participants will receive treatment by radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: All participants will receive treatment by radiotherapy
Study: NCT02807792

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Perianal access device
Description: Perianal access device
Study: NCT02005081

Intervention type: DEVICE
Group type: OTHER
Intervention: Actifuse SHAPE
Description: Actifuse Synthetic Bone Graft substitutes mixed with bone marrow aspirate in cervical spine fusion. Actifuse is a synthetic, porous, silicate-substituted hydroxyapatite and has shown that this maximizes a favorable bony response.

Intervention type: DEVICE
Group type: OTHER
Intervention: Autograft with Demineralized Bone Matrix
Description: autograft mixed with demineralized bone matrix in cervical spine fusion.
Study: NCT04331353

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator 1 (tailored approach)
Description: Tailored to a child's sensitization status. Components include, education, cockroach baiting, mattress and bed covers, high efficiency particulate air (HEPA) vacuum cleaner, air purifier.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator 2 (insecticidal bait)
Description: Cockroach bait
Study: NCT03622853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroid (shincort)
Description: intraarticular shincort 40mg / 4ml mixed with 2% xylocaine and Normal saline
Study: NCT01222637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CetuGEX™

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CetuGEX™
Study: NCT05291000

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Role of Training and Reminder Wristwatche in Hypertension (RoT-ReWiH)
Description: The present study revealed that multiple interventions such as home visits to elderly hypertensive patients, training program, telephone counseling, and the use of medication reminder wristwatch are effective in increasing treatment adherence and self-efficacy, and in controlling blood pressure. In this direction, health professionals working in primary care are recommended that they make regular home visits, encourage patients to take responsibility for health, and organize regular and interdisciplinary training and counseling programs in the management of hypertension.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Role of Training and Reminder Wristwatche in Hypertension (RoT-ReWiH)
Description: The present study revealed that multiple interventions such as home visits to elderly hypertensive patients, training program, telephone counseling, and the use of medication reminder wristwatch are effective in increasing treatment adherence and self-efficacy, and in controlling blood pressure. In this direction, health professionals working in primary care are recommended that they make regular home visits, encourage patients to take responsibility for health, and organize regular and interdisciplinary training and counseling programs in the management of hypertension.
Study: NCT03635307

Intervention type: OTHER
Intervention: End Tidal Carbon Dioxide measure
Description: End Tidal Carbon Dioxide measures before and after a volume expansion of 250ml of crystalloid in the operating room.
Study: NCT03995901

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FCR001
Description: FCR001 is a cryopreserved allogeneic stem cell therapy derived from mobilized peripheral blood of the kidney donor that is delivered as a single dose with a non- myeloablative conditioning regimen. FCR001 contains the donor's CD34+ cells, facilitating cells, and αβ T cells.
Study: NCT01704820

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retroflexion in the right colon
Study: NCT04309864

Intervention type: DEVICE
Group type: OTHER
Intervention: Use of CMAP app for education (in-hospital)
Description: Clinicians will use the updated CMAP system during patient education for prevention of pressure injuries with Veterans with SCI who are completing their initial rehabilitation.

Intervention type: DEVICE
Group type: OTHER
Intervention: Use of CMAP app (in-home)
Description: The Veteran will use the CMAP system at home for two weeks during their daily routines.
Study: NCT01176773

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hyaluronic acid gel
Description: Dosage per Investigator's discretion to obtain lip treatment goal; 1 touch-up treatment is allowed 14 days after initial treatment. Maximum total volume per subject is 2.0 mL
Study: NCT00705835

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rsPSMA protein plus Alhydrogel® vaccine
Description: The assigned dose of rsPSMA protein plus Alhydrogel® vaccine will be administered subcutaneously to random sites on the upper arm and upper leg at weekly intervals for 3 weeks. This will be followed by a 4-week break and then a fourth vaccination during week 7. The vaccination site will rotate to a different quadrant with each administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rsPSMA protein plus Alhydrogel® vaccine
Description: The assigned dose of rsPSMA protein plus Alhydrogel® vaccine will be administered subcutaneously to random sites on the upper arm and upper leg at weekly intervals for 3 weeks. This will be followed by a 4-week break and then a fourth vaccination during week 7. The vaccination site will rotate to a different quadrant with each administration.
Study: NCT05397860

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation using gradual radiofrequency energy delivery with Octopus electrodes
Description: Radiofrequency ablation (RFA) will be performed by using multi-VIVA generator and Octopus electrodes. Three electrodes will be placed on the tumor under ultrasonography (US)-computed tomography (CT)/magnetic resonance (MR) fusion tool guidance. The electrodes will be cooled with saline, and radiofrequency (RF) will be applied to two of three electrodes at the same time for about 6 to 30 minutes depending on the tumor size. The temperature will be maintained at 90-100 °C. The RF energy will starts at 60 watts and increase by 10 watts every 30 seconds for the first 3 minutes, and then increases gradually by 10 watts per minute after reaching 100 watts.
Study: NCT04023825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: suprazygomatic maxillary nerve block
Description: in the experimental group, each child will profit from the realization of a suprazygomatic maxillary nerve block.
Study: NCT00196872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicine
Description: Epirbubicne is given

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicine
Description: Epirbubicne is given

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicine
Description: Epirbubicne is given

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicine
Description: Epirbubicne is given

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is given

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is given

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is given

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is given

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxol
Description: Taxol is given

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxol
Description: Taxol is given

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxol
Description: Taxol is given

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxol
Description: Taxol is given

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeloda
Description: Xeloda is given

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeloda
Description: Xeloda is given

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibandronat
Description: Ibandronat is given

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibandronat
Description: Ibandronat is given
Study: NCT03865147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tri-Solfen Gel (Lidocaine HCl, Bupivacaine HCl, Adrenaline Acid Tartrate /Cetrimide)
Description: Investigational Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tri-Solfen Gel (Lidocaine HCl, Bupivacaine HCl, Adrenaline Acid Tartrate /Cetrimide)
Description: Investigational Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tri-Solfen Gel (Lidocaine HCl, Bupivacaine HCl, Adrenaline Acid Tartrate /Cetrimide)
Description: Investigational Drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMLA cream
Description: Active Comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMLA cream
Description: Active Comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMLA cream
Description: Active Comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Post Operative Analgesia (Paracetamol, Ibuprofen)
Description: Standard of Care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Post Operative Analgesia (Paracetamol, Ibuprofen)
Description: Standard of Care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post Operative Analgesia (Paracetamol, Ibuprofen)
Description: Standard of Care
Study: NCT00279773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKI258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKI258
Study: NCT01384422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0634

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GLPG0634
Study: NCT01862640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole, OPC-34712
Description: Once-daily, tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole, OPC-34712
Description: Once-daily, tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Once-daily, tablets
Study: NCT02655302

Intervention type: OTHER
Group type: OTHER
Intervention: Sample collecting
Description: Collect sputum, blood and nasopharyngeal swab during the exacerbation and at steady state 8 to 16 weeks later.

Intervention type: OTHER
Group type: OTHER
Intervention: Sample collecting
Description: Collect sputum, blood and nasopharyngeal swab during the exacerbation and at steady state 8 to 16 weeks later.

Intervention type: OTHER
Group type: OTHER
Intervention: Lung function measure
Description: Measure lung function and follow it during 4 years

Intervention type: OTHER
Group type: OTHER
Intervention: Lung function measure
Description: Measure lung function and follow it during 4 years
Study: NCT04189237

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: needles were inserted to Taixi (KI3), Taichong (LR3), Zusanli(ST36), Yanglingquan (GB34), contralateral to the operated leg and deqi sensation elicited at acupoints.
Study: NCT03770559

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimal Invasive RAMPS
Description: Eligible patients diagnosed as left-side pancreatic cancer in MI-RAMPS group will be treated by minimal invasive RAMPS surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open RAMPS
Description: Eligible patients diagnosed as left-side pancreatic cancer in Open-RAMPS group will be treated by open invasive RAMPS surgery
Study: NCT01339741

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3, oral supplement, 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, oral route, 12 weeks
Study: NCT03458286

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BRH-A2 wound healing device
Description: Combined ultrasound and electric current stimulation (CUSECS) is a combination therapy provided by the BRH-A2 wound healing device. This study is testing the effectiveness of the treatment CUSECS. The electric current stimulation is provided by attaching small electrodes around the ulcers. A probe is used on the ulcers to provide the ultrasound waves. Both aiming to increase the blood flow to an area to increase wound healing.
Study: NCT02643836

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: PEMF
Description: The PEMF device (Rio Grande Neurosciences - RGN) the investigators would be testing has been shown to have significant anti-inflammatory effects in animals and humans and an excellent safety profile in several clinical studies. Key findings demonstrated that PEMF-treated rodents with a closed-head TBI exhibited a 5-fold decrease in IL-1b in the cerebral spinal fluid, an outcome associated with decreased neuropathology and improved function.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEMF
Description: The PEMF device (Rio Grande Neurosciences - RGN) the investigators would be testing has been shown to have significant anti-inflammatory effects in animals and humans and an excellent safety profile in several clinical studies. Key findings demonstrated that PEMF-treated rodents with a closed-head TBI exhibited a 5-fold decrease in IL-1b in the cerebral spinal fluid, an outcome associated with decreased neuropathology and improved function.
Study: NCT02687425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: 15mg/day,po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: 400mg/day,po
Study: NCT01975428

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DM Pgm + device
Description: Disease management program plus a device corresponding to an individual's disease(s):~iBGStar - iPhone enabled capillary blood glucose meter. Subjects test blood glucose up to 4 times per day, every day.~Withings BP monitor - iPhone enabled home blood pressure monitor. Subjects test their blood pressure 2 times per day, up to 3 days per week.~iPhone enabled Alive Cor ECG monitor. Participants take an ECG reading only when symptomatic.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: All study participants, including participants randomized to the control arm, were enrolled in the HealthComp disease management program, which involved outreach by HealthComp nursing staff for purposes of relaying medical education and wellness information with regard to disease prevention and chronic disease management.
Study: NCT03082703

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messaging
Description: Subjects contacted 3 times weekly via text messaging for the study period.
Study: NCT01644344

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No-Xray
Description: Treatment group: these patients will not have routine post-operative in hospital radiographs, or radiographs in clinic at two weeks. After examining the patient, the surgeon or resident can order radiographs if required at any time. The decision will be made based on patient complaints of increased pain, appearance of abuse of the splint or cast suggesting lack of compliance or visible clinical deformity of the limb. The reason leading to radiographs will be documented by the ordering physician. If radiographs are ordered based on a wound complication, this will be specifically documented. Radiographic findings will be documented on a form identical to that used for the control group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Xray
Study: NCT01394471

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal Oxytocin Spray
Description: 6 insufflations (24IU of oxytocin total) given twice daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin Spray
Description: 6 insufflations (24IU of oxytocin total) given twice daily for 12 weeks
Study: NCT03118349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVT-1075
Description: MVT-1075 administered in two fractions, with each administration of MVT-1075 preceded by blocking dose of MVT-5873.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVT-1075
Description: MVT-1075 administered in two fractions, with each administration of MVT-1075 preceded by blocking dose of MVT-5873.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVT-5873
Description: MVT-5873 administered intravenously as a non-radioactive blocking agent prior to administration of MVT-1075.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVT-5873
Description: MVT-5873 administered intravenously as a non-radioactive blocking agent prior to administration of MVT-1075.
Study: NCT03988322

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-dose CT screening with quantitative assessment and management of imaging biomarkers
Description: Participants will be screened with a low-dose CT (a Philips 256-slice CT system). The CT images will be obtain according to the pre-defined CT scan protocol. This CT protocol is developed for quantitative assessment of lung nodules, COPD and coronary artery calcium. Detected lung nodules will be managed according to the European volume-based protocol, based on the volume and volume doubling time of lung nodule. COPD will be management according to the result of lung function test. The imaging biomarkers (eg., emphysema index, airway wall thickness, and coronary artery calcium ) will be quantitatively registered. In addition, a number of participants' characteristics will be collected: physical examination (weight, height, blood pressure), laboratory measurements (eg., fasting plasma glucose, total cholesterol, HDL-cholesterol). The social-demographic characteristics, risk factors of the 3 diseases, and health status of the participants will be collected through questionnaires.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose CT screening with visual assessment and management of imaging biomarkers
Description: Participants will be screened with a low-dose CT (a Philips 64 MDCT system). The CT images will be obtain according to the routine CT scan protocol for lung cancer screening in the hospital. Detected lung nodules will be managed according to the diameter of the nodule based on the NCCN Clinical Practice Guideline in Oncology for Lung Cancer Screening. Detected emphysema and/or bronchial wall thickness, coronary artery calcium will be qualitatively recorded (yes/no).